John Howard Hutchinson

This inventor holds 112 USPTO granted patents and 35 published patent applications, plus 6 CIPO patents and 19 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D401-14). Top assignees: Merck + Co., Inc., Panmira Pharmaceuticals, LLC, Amira Pharmaceuticals, Inc.. Active years: 1993-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Howard Hutchinson. Retrieved from https://idiyas.com/inventor/john-howard-hutchinson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 112 (Patent Applications = 35)

% Patents Active = 66.1

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 19 (Patent Applications = 50)

Average Co-Inventor Count = 3.7

ph-index = 16

Forward Citations = 1,109(Granted Patents)

Forward Citations (Not Self Cited) = 911(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Montreal, CA (1993 - 1995)
Philadelphia, PA (US) (1994 - 2006)
La Jolla, CA (US) (2003 - 2020)
San Diego, CA (US) (2011 - 2023)

Company Filing History:

Panmira Pharmaceuticals, LLC

patents

18 out of 23

Amira Pharmaceuticals, Inc.

patents

4. 18 out of 212

Merck Frosst Canada, Inc.

Sabre Therapeutics LLC

patents

7. 3 out of 99

Sanford Burnham Prebys Medical Discovery Institute

patents

8. 1 out of 1

Df 2024 IP Acquisition, LLC

patent

9. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

10. 1 out of 99

Sanford-Burnham Medical Research Institute

patents

where one patent can have more than one assignee

Years Active: 1993-2026

Loading Chart...

Areas of Expertise:

Autotaxin Inhibitors

Lysyl Oxidase-like 2 Inhibitors

Receptor Antagonists

Metabotropic Glutamate Receptor

5-Lipoxygenase-activating Protein

Heterocyclic Compounds

Quinolinone Compounds

Fluorinated Compounds

Pharmaceutical Compositions

Neurological Uses

Fibrosis Treatment

112 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637436 - Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof (2026-05-26),

2. 12458627 - Autotaxin inhibitors and uses thereof (2025-11-04),

3. 12268668 - Autotaxin inhibitor compounds (2025-04-08),

4. 11793797 - Uses of a lysyl oxidase-like 2 inhibitor (2023-10-24),

5. 11779568 - Autotaxin inhibitor compounds (2023-10-10),

6. 11447453 - Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof (2022-09-20),

7. 11358936 - Lysyl oxidase-like 2 inhibitors and uses thereof (2022-06-14),

8. 11344533 - Autotaxin inhibitor compounds (2022-05-31),

9. 11072585 - Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof (2021-07-27),

10. 11058676 - Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof (2021-07-13),

11. 10766860 - Lysyl oxidase-like 2 inhibitors and uses thereof (2020-09-08),

12. 10688081 - Autotaxin inhibitor compounds (2020-06-23),

13. 10632104 - Autotaxin inhibitors and uses thereof (2020-04-28),

14. 10597367 - Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof (2020-03-24),

15. 10588900 - Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof (2020-03-17),

Title: **John Howard Hutchinson: Pioneering Biopharmaceutical Innovations**

Introduction

John Howard Hutchinson, based in San Diego, California, is an accomplished inventor with an impressive portfolio of 109 patents. His work primarily focuses on biopharmaceutical innovations, contributing significantly to advancements in medical treatments and therapies. Hutchinson's research has led to groundbreaking discoveries in the fields of enzyme inhibitors and pharmaceutical compositions.

Latest Patents

Two of Hutchinson's latest patents highlight his innovative contributions to the medical field. The first patent involves the "Uses of a lysyl oxidase-like 2 inhibitor," which describes the application of LOXL2 inhibitors in treating or preventing various conditions associated with LOXL2 activity. The second patent, titled "Autotaxin inhibitor compounds," outlines compounds that function as autotaxin inhibitors, including methods for their development, formulation into pharmaceutical compositions, and utilization in treating disorders linked to autotaxin activity.

Career Highlights

Throughout his career, Hutchinson has worked with several prominent organizations, including Merck & Company, Inc. and Panmira Pharmaceuticals, LLC. His tenure at these companies has allowed him to develop and refine innovative biopharmaceutical strategies that address significant medical challenges.

Collaborations

Hutchinson's success is also attributed to his collaborations with notable colleagues, including Nicholas Simon Stock and Jeannie M Arruda. These partnerships have facilitated the exchange of ideas and propelled advancements in their respective research areas.

Conclusion

John Howard Hutchinson stands out as a key figure in biotechnology, with his numerous patents reflecting his relentless pursuit of innovation. His contributions are not only significant in their scientific merit but also hold the potential to positively impact numerous lives through improved medical treatments. As he continues to pave the way for future advancements, Hutchinson remains a noteworthy inventor in the realm of biopharmaceuticals.

Profile summary based on public USPTO records.